Clinical Conundrums in Immuno-Oncology

Bladder cancer

1 How do you define a high risk of recurrence? See the videos

Dr. Girish Kulkarni Physician - Answer 00:03:52

3 How do you manage patients who refuse or are ineligible for chemotherapy? See the videos

Dr. Aly-Khan Lalani Physician - Answer 00:04:17
Dr. Michel Pavic Physician - Answer 00:02:26

4 What are best practices with regards to the collaboration between medical oncology and urology to ensure seamless patient care? See the videos

Dr. Nimira Alimohamed Physician - Answer 00:04:37
Dr. Girish Kulkarni Physician - Answer 00:06:20

5 What are the data supporting adjuvant I-O treatment options in UC? See the videos

Dr. Aly-Khan Lalani Physician - Answer 00:02:00

Kidney cancer

1 What are the characteristics that affect your decision to use dual I-O vs. I-O and a TKI? See the videos

Dr. Christian Kollmannsberger Physician - Answer 00:06:41

2 What is the role of the treatment-free interval in RCC? See the videos

Dr. Christian Kollmannsberger Physician - Answer 00:03:54

3 In which patients is the use of adjuvant I-O indicated? See the videos

Dr. Aly-Khan Lalani Physician - Answer 00:01:52

4 How does the use of adjuvant I-O affect your use of I-O therapy in the metastatic setting? See the videos

Dr. Aly-Khan Lalani Physician - Answer 00:02:41

5 What is the role for RT in the treatment of RCC? See the videos

Dr. Christian Kollmannsberger Physician - Answer 00:05:18

6 How does the presence of sarcomatoid features influence your treatment decisions in RCC? See the videos

Dr. Aly-Khan Lalani Physician - Answer 00:02:42

Lung cancer

1 How do you choose between neoadjuvant and adjuvant I-O in resectable NSCLC? See the videos

Dr. Jonathan Spicer Physician - Answer 00:02:10

2 What types of biomarker testing and pathology reports are necessary pre- and post-surgery for informed treatment planning? See the videos

Dr. Barbara Melosky Physician - Answer 00:07:14

3 How do you facilitate multidisciplinary collaboration for treatment planning before and after surgery? See the videos

Dr. Jonathan Spicer Physician - Answer 00:02:19

4 What is the chance that treating NSCLC with I-O and chemotherapy in the neoadjuvant setting could prevent a patient from ever undergoing curative intent surgery? See the videos

Dr. Jonathan Spicer Physician - Answer 00:03:10

5 What are optimal sequencing strategies in the first-line and second-line metastatic NSCLC settings? See the videos

Dr. Rosalyn Juergens Physician - Answer 00:03:12

6 Which patient factors influence your treatment selection when choosing between dual I-O plus chemotherapy and I-O plus chemotherapy in the first-line metastatic NSCLC setting? See the videos

Dr. Daniel Breadner Physician - Answer 00:05:11
Dr. Kevin Jao Physician - Answer 00:06:30

7 Which disease factors influence your treatment selection when choosing between dual I-O plus chemotherapy and I-O plus chemotherapy in the first-line metastatic NSCLC setting? See the videos

Dr. Daniel Breadner Physician - Answeer 00:04:31
Dr. Kevin Jao Physician - Answer 00:07:50
Dr. Barbara Melosky Physician - Answer 00:06:05

8 In patients with high PD-1 expression, what factors would determine whether I-O would be given as monotherapy or in combination with chemotherapy or 9-LA? See the videos

Dr. Rosalyn Juergens Physician - Answer 00:02:46

9 What treatment would you consider for a non-smoking patient with no driver mutations? See the videos

Dr. Kevin Jao Physician - Answer 00:05:51

10 What is your level of comfort with managing the toxicity associated with dual I-O in metastatic NSCLC? See the videos

Dr. Kevin Jao Physician - Answer 00:06:28
Dr. Barbara Melosky Physician - Answer 00:02:07

11 What are optimal sequencing strategies for patients with MPM and do they differ for MPM with epithelioid vs non-epithelioid histology? See the videos

Dr. Kevin Jao Physician - Answer 00:06:15

Skin cancer

1 How do you treat patients who have progressed within 6 months of adjuvant anti-PD1 therapy? See the videos

Dr. John Walker Physician - Answer 00:04:51

2 What is the optimal treatment sequencing for BRAF-mutated disease in the metastatic setting? See the videos

Dr. John Walker Physician - Answer 00:03:21

3 What is the clinical relevance of TFS and the TFI? See the videos

Dr. John Walker Physician - answer 00:02:41

4 How does the length of follow-up in clinical trial data impact your treatment selection? See the videos

Dr. John Walker Physician - Answer 00:03:39

5 How do you select which patients to treat in the adjuvant setting? See the videos

Dr. Robyn Macfarlane Physician - Answer 00:03:00

6 What is the clinical relevance of RFS in the absence of OS data? See the videos

Dr. Robyn Macfarlane Physician - Answer 00:02:26

7 How will the introduction of anti-lymphocyte-activation gene 3 (LAG-3) therapy impact treatment selection after anti-PD1 therapy? See the videos

Dr. Robyn Macfarlane Physician - Answer 00:04:48

8 What is the MOA of LAG3? See the videos

Dr. Robyn Macfarlane Physician - Answer 00:01:05

Upper gastrointestinal cancer

1 What is the clinical relevance of endpoints such as DFS and MDFS when selecting adjuvant therapy in the absence of OS data? See the videos

Dr. Stephanie Snow Physician - Answer 00:02:43

2 What treatment regimens would you consider in the case of patient with GEJ adenocarcinoma for whom the PD-L1 CPS is unknown? See the videos

Dr. Kim Ma Physician - Answer 00:06:58

3 What treatment regimens would you consider in the case of a patient with metastatic esophageal adenocarcinoma? See the videos

Dr. Howard Lim Physician - Answer 00:02:30

4 What data do we have to support the long-term efficacy of I-O treatment options in the first-line metastatic setting? See the videos

Dr. Stephanie Snow Physician - Answer 00:01:56

5 What is the role of biomarkers in treatment selection for your patients with metastatic uGI cancers? See the videos

Dr. Stephanie Snow Physician - Answer 00:03:15

6 For your patients with metastatic uGI cancer on I-O plus chemotherapy, when do you consider stopping chemotherapy and how do you do it? See the videos

Dr. Daniel Breadner Physician - Answer 00:03:28
Dr. Kim Ma Physician - Answer 00:04:55

7 How does your multidisciplinary team make the decision to treat with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel or carboplatin, paclitaxel, and radiation in the adjuvant setting? See the videos

Dr. Daniel Breadner Physician - Answer 00:03:12

8 How do you approach discussing adjuvant treatment options with your eligible patients? See the videos

Dr. Daniel Breadner Phycisian - Answer 00:02:11
Dr. Howard Lim Physician - Answer 00:02:35

9 What data supports the role of adjuvant I-O in uGI cancers? See the videos

Dr. Howard Lim Physician - Answer 00:01:12

10 How do you balance risks vs. benefits, including QoL, OS, and toxicities, when making adjuvant treatment decisions? See the videos

Dr. Howard Lim Physician - Answer 00:02:41

11 What treatment regimens would you consider in the case of a young female patient with metastatic gastric adenocarcinoma? See the videos

Dr. Kim Ma Physician - Answer 00:10:48

Immune related adverse events

1 What are some strategies to mitigate the negative effects of prolonged corticosteroid use for management of irAEs? See the videos

Dr. Stephanie Snow Physician - Answer 00:06:42

2 What are some of the challenges in managing pneumonitis? See the videos

Dr. Rosalyn Juergens Physician - Answer 00:02:39

3 How do you manage patients with colitis and what is the role of gastroenterology in caring for these patients? See the videos

Dr. Daniel Breadner Physician - Answer 00:04:02
Dr. Kim Ma Physician - Answer 00:06:06

4 How do you counsel patient before starting I-O therapy? See the videos

Dr. Daniel Breadner Physician - Answer 00:05:19

5 When do you use corticosteroids vs. biologics early in irAE management? See the videos

Dr. Barbara Melosky Physician - Answer 00:03:24

6 What is the Canadian Community of Practice (CoP) on irAEs and what is its value? See the videos

Dr. Stephanie Snow Physician - Answer 00:01:22

CCIO: Clinical Conundrums in Immuno-Oncology